EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars to Treat Rare Diseases and Key Leadership Changes
09 mai 2016 16h00 HE
|
EPIRUS Biopharmaceuticals, Inc.
New strategy to focus exclusively on BOW080 (eculizumab biosimilar) and BOW070 (tocilizumab biosimilar) in rare diseases with a combined target market opportunity of close to $6 billion of innovator...
EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 Financial Results and Provides Business Update
15 mars 2016 06h00 HE
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, March 15, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play biosimilar company focused on the global development and commercialization of biosimilar...
EPIRUS Biopharmaceuticals to Release Fourth Quarter and Fiscal Year 2015 Financial Results and Provide Business Update
01 mars 2016 08h00 HE
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, March 01, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play biosimilar company focused on the development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)
09 févr. 2016 07h00 HE
|
EPIRUS Biopharmaceuticals, Inc.
UNIFORMi Study builds on prior successful Phase 1 and Phase 3 studiesIntended to support harmonized global filing for BOW015 in 2017BOW015 is a biosimilar for Remicade®, which had global sales of...
EPIRUS Biopharmaceuticals to Participate in Bloomberg Intelligence Healthcare Event on February 12
05 févr. 2016 16h01 HE
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Feb. 05, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals to Present at LEERINK Partners 5th Annual Global Healthcare Conference
03 févr. 2016 09h00 HE
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Feb. 03, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals Provides Clinical Program Update on BOW015 (Infliximab Biosimilar)
16 nov. 2015 06h05 HE
|
EPIRUS Biopharmaceuticals, Inc.
Readiness for on-time initiation of pivotal global registration study with completion of manufacturing process lockBOW015 remains on track for 2017 global filingBOW015 targets large market opportunity...
EPIRUS Biopharmaceuticals Reports Third Quarter 2015 Financial Results & Provides Business Update
16 nov. 2015 06h00 HE
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Nov. 16, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals Reschedules Its Third Quarter 2015 Financial Results Conference Call and Webcast
11 nov. 2015 16h05 HE
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Nov. 11, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals Appoints Industry Veteran Vincent E. Aurentz as Chief Business Officer
10 nov. 2015 08h00 HE
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Nov. 10, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...